Immunic to participate in investor and scientific conferences in february

New york , feb. 4, 2025 /prnewswire/ --  immunic , inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in february: february 10-11: bio ceo & investor conference 2025. daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking